There are a number of other drug-like molecules with a similar mechanism of action as DMF, but they directly interfere with the Keap1/NRF2 interaction and show more prospects for targeting NRF2 in neurodegenerative diseases (Bertrand et al., 2015; Quinti et al., 2016). The gene discussed is KEAP1; the disease is neurodegenerative disease.